GSK plc





Market Closed - London S.E. 11:35:00 2024-02-23 am EST 5-day change 1st Jan Change
1,672 GBX +0.22% Intraday chart for GSK plc -0.24% +15.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vir Biotechnology, GSK Terminate Collaboration on Flu DJ
Drugs, fashion and chips - the STOXX 600's 'Magnificent 4' RE
Moderna reports surprise profit, sets out road map for RSV vaccine RE
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People MT
GSK: 'remarkable' results in HIV treatment CF
GSK : Gets a Buy rating from Deutsche Bank ZD
GSK reports encouraging results for ViiV's Cabenuva HIV treatment AN
ViiV's Long-acting Injectable HIV Drug Shown More Effective than Daily Pills in Phase 3 Study MT
AJ Bell founder to join Applied Nutrition ahead of IPO - Sky AN
Diageo welcomes GSK's CFO as non-executive director AN
Global markets live: Airbus, Cisco, BAE, Salesforce, Deere... Our Logo
GSK Completes Aiolos Bio Acquisition MT
Berenberg Lifts GSK PT, Maintains Buy Rating MT
GSK: has completed the acquisition of Aiolos Bio CF
Jefferies cuts Kingfisher but Citi raises AN
British stocks rise on recession-induced rate cut hopes Our Logo
GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio AN
GSK Closes $1.4 Billion Purchase of Aiolos Bio MT
GSK completes acquisition of Aiolos Bio for up to $1.4 bln RE
GSK : Berenberg maintains a Buy rating ZD
GSK plc completed the acquisition of Aiolos Bio, Inc. from a group of shareholders. CI
GSK to License Elsie Biotechnologies' Discovery Platform MT
GSK: license option exercised with Elsie CF
The market faces a choice Our Logo
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
16.72 GBP
Average target price
19.49 GBP
Spread / Average Target
1st Jan change Capi.
+15.32% 86 012 M $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock GSK plc - London S.E.
  4. News GSK plc
  5. European Equities Traded in the US as American Depositary Receipts Sharply Higher Thursday
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.